Docstoc

Robbins Umeda LLP Announces Investigation of TomoTherapy Incorporated

Document Sample
Robbins Umeda LLP Announces Investigation of TomoTherapy Incorporated Powered By Docstoc
					Robbins Umeda LLP Announces Investigation of
TomoTherapy Incorporated
February 01, 2010 04:08 PM Eastern Time  

SAN DIEGO--(EON: Enhanced Online News)--Robbins Umeda LLP has commenced an investigation into
possible mismanagement at TomoTherapy Incorporated ("TomoTherapy" or the "Company") (NASDAQ: TOMO).
TomoTherapy develops, manufactures, markets, and sells a radiation therapy system for the treatment of cancer. All
of the Company's revenues are derived from the sale of its radiation therapy system. The Company was founded in
1997 and is headquartered in Madison, Wisconsin.

Robbins Umeda LLP's investigation concerns whether certain officers and/or directors issued a series of materially
false and misleading statements regarding TomoTherapy's revenues and net income. It appears that the Company
withheld material information from the investing public between May 9, 2007 and April 17, 2008, regarding its
revenues from backlogged multi-unit orders and earnings guidance. Then, on April 17, 2008, TomoTherapy
disclosed that a large percentage of the Company's orders would remain in its backlog into late 2008 and 2009,
rather than being delivered in the beginning of 2008 as expected. This increased time in backlog resulted in a
corresponding delay in recognition of revenue. After the release of this news, TomoTherapy's common stock
declined 32%, on extraordinary trading volume in excess of eight million shares.

A number of securities fraud class actions have been filed on behalf of shareholders who purchased or otherwise
acquired TomoTherapy stock between May 9, 2007 and April 17, 2008, seeking recovery from TomoTherapy and
certain of its officers for the damages they have suffered as a result of the officers' alleged mismanagement of the
Company. Securities class actions like these can potentially cause additional damage to the Company.

If you purchased TomoTherapy stock before May 9, 2007, continue to hold your shares, and would like more
information about your rights as a shareholder, please contact attorney Lauren Levi at 800-350-6003 or by e-mail at
llevi@robbinsumeda.com.

Robbins Umeda LLP is a California-based law firm with significant experience representing investors in shareholder
derivative and securities fraud class actions. For more information about the firm, please visit our website at
http://www.robbinsumeda.com.

Advertisement

Contacts
Robbins Umeda LLP
Lauren Levi, 800-350-6003
llevi@robbinsumeda.com

Permalink: http://eon.businesswire.com/news/eon/20100201007118/en

				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:24
posted:2/1/2010
language:English
pages:1
Description: SAN DIEGO--(EON: Enhanced Online News)--Robbins Umeda LLP has commenced an investigation into possible mismanagement at TomoTherapy Incorporated ("TomoTherapy" or the "Company") (NASDAQ: TOMO). TomoTherapy develops, manufactures, markets, and sells a radiation therapy system for the treatment of cancer. All of the Company's revenues are derived from the sale of its radiation therapy system. The Company was founded in 1997 and is headquartered in Madison, Wisconsin. Robbins Umeda LLP's investigat a style='font-size: 10px; color: m
EON: Enhanced Online News EON: Enhanced Online News http://eon.businesswire.com
About At EON: Enhanced Online News, we show you how to make your online press release thrive. If you want to drive traffic to your website, generate sales leads, make an announcement, or promote a new product, EON: Enhanced Online News delivers the online visibility that you need. EON: Enhanced Online News powered by Business Wire.